The trial has not failed, just not reaching some ambiguous number. Eli Lily already has the better drug in that regard, but many patients and doctors seem to prefer Ozempic, as it has less pronounced side-effects. I am sure that more competitors will appear too, but I think that there are some great people and great history of innovation behind Novo Nordisk. They also have the scale and production capacity to deliver to market, something that most competitors dont. And I have learned to appreciate the corporate culture around the Novo Nordisk Foundation(its the biggest charitable foundation). I mean its not just the pharma, they are also behind Novozymes(now Novonesis), which is working on plastics eating bacteria and enzymes. This is some good stuff, so I think this falling knife is worth catching.